Privacy Policy
Signals Blog

Contributors

Categories

Right Turn: On the right track to health and prosperity

The subway map is a popular metaphor for showing how to get from point A to point B with many stops along the way. It can be simple, with only a few intersecting lines of tracks – Toronto’s (shockingly inadequate) two-line system comes to mind – or complicated, like...

Right Turn: Making science fun and relatable

A popular marketing strategy is to reach (insert demographic) “where they live.” Science Genius appears to have taken that concept to heart when it comes to kids and science. Science Genius, launched in December 2012 by Christopher Emdin, the musician GZA and the...

Right Turn: Resources for scientists

I’ve read enough PhD Comics to understand that being a scientist is hard. (I work with them too, but I’m saving those stories for my tell-all autobiography.) Recently I stumbled upon* what I believe could be a useful resource for scientists to make their lives a...

Understanding immortality, one slice at a time

Jovana Drinjakovic is a science writer with a background in cell and developmental biology. After completing her PhD in Cambridge (the old one) and a postdoc at the Hospital for Sick Children in Toronto, Jovana decided to switch gears and enrolled in a journalism...

Right Turn: Henrietta Lacks immortalized on film

Arguably one of the most popular science books ever written is heading to the big screen. Tech Insider calls The Immortal Life of Henrietta Lacks “the most important science book of our time.” And with Oprah Winfrey cast as Henrietta’s daughter, you will be hard...

The race to develop senescent cell clearance therapies

A growing focus of biomedical research and regenerative medicine is the effort to target the aging process itself, by either slowing or reversing the accumulation of cellular and molecular damage that drives age-related functional decline. The goal is to develop new...

Update from the Clinic: March

Welcome to your Update from the Clinic for the month of March. Undoubtedly the big news in March came from Vericel, which saw its stock double after reporting positive topline results from its Phase 2b study in heart failure. There were also some first dosings and...

Subscribe to Signals

Subscribe to our blog list to receive the latest news and updates.

You have Successfully Subscribed!